STAT

Opinion: Online sellers of designer drugs are a dark partner in the opioid epidemic

Online companies that openly sell drug-like substances that have never been approved by the FDA are contributing to the addiction epidemic.
Designer drugs, which are sold openly and legally, are often marketed as "not for consumption" or "for research purposes only."

One of Max’s friends taught him an easy way to buy shady drugs. What he learned almost killed him, and it opened my eyes to a hiding-in-plain-sight source of dangerous drugs that is amplifying the opioid epidemic.

When Max (not his real name) developed pancreatitis a decade ago, his physicians prescribed opioids to ease his extreme pain. When he experienced anxiety between episodes of pancreatitis, his physicians prescribed a benzodiazepine.

Benzodiazepines are used to treat anxiety and insomnia, symptoms they can effectively resolve, at least in the short term. Textbooks euphemistically call these drugs anxiolytics and hypnotics. An estimated 1 in 20 Americans use them each year. When taken long term, benzodiazepines can cause physical dependence. Their sudden discontinuation can be lethal.

The combination of opioids and benzodiazepines is common — that between 12 percent and 19 percent of patients who are prescribed an opioid are also prescribed a benzodiazepine. It is also dangerous, since both drugs increase the risk of slowing or stopping breathing. In fact, benzodiazepines are involved in of overdose deaths attributed to prescription drugs.

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Cigna Biosimilar Plans, A Vertex Deal In South Africa, And More
Cigna plans to make copies of AbbVie's Humira arthritis drug available with no out-of-pocket payment to eligible patients in the U.S.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About CVS And Humira Biosimilars, Schumer’s Broken Insulin Promise, And More
New prescriptions for biosimilar versions of Humira, one of the best-selling drugs in the U.S., surged to 36% from just 5% during the first week of April.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Biocon Eyeing Weight Loss Drugs, Sanofi Layoffs, And More
Biocon is pivoting to weight loss drugs as patents for the blockbuster medicines start to expire, unleashing a coming wave of generics.

Related Books & Audiobooks